Sacutan
Generic Name
Sacubitril and Valsartan
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sacutan 97 mg tablet | ৳ 120.00 | ৳ 1,200.00 |
Description
Overview of the medicine
Sacutan is a combination medication containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker). It is used to treat chronic heart failure with reduced ejection fraction.
Uses & Indications
Dosage
Adults
Initial dose: 49 mg sacubitril / 51 mg valsartan orally twice daily. The dose should be doubled after 2-4 weeks to the target maintenance dose of 97 mg sacubitril / 103 mg valsartan orally twice daily, as tolerated.
Elderly
No specific dose adjustment is required in elderly patients, but careful monitoring is recommended.
Renal_impairment
Mild-to-moderate renal impairment: No initial dose adjustment. Severe renal impairment (eGFR <30 mL/min/1.73m²): Consider a lower initial dose of 24 mg sacubitril / 26 mg valsartan twice daily.
How to Take
Take orally twice daily, approximately 12 hours apart. Can be taken with or without food.
Mechanism of Action
Sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides, leading to increased levels of these peptides. Valsartan blocks the angiotensin II type 1 (AT1) receptor, inhibiting the effects of angiotensin II.
Pharmacokinetics
Onset
Reduction in blood pressure can be observed within a few days; clinical benefits in heart failure typically take several weeks.
Excretion
LBQ657 and valsartan are primarily excreted in urine and feces.
Half life
Active metabolite LBQ657: approximately 11.3 hours; Valsartan: approximately 9.9 hours.
Absorption
Sacubitril is a prodrug, rapidly converted to the active metabolite LBQ657. Valsartan is well absorbed. Peak plasma concentrations for LBQ657 and valsartan are reached in 2 hours and 1.5 hours, respectively.
Metabolism
Sacubitril is metabolized to its active metabolite LBQ657 by esterases. Valsartan is minimally metabolized (less than 20%).
Side Effects
Contraindications
- •Hypersensitivity to any component.
- •Concomitant use with ACE inhibitors (within 36 hours of switching).
- •History of angioedema related to previous ACE inhibitor or ARB therapy.
- •Severe hepatic impairment, biliary cirrhosis, or cholestasis.
- •Pregnancy.
Drug Interactions
NSAIDs
May reduce the antihypertensive effect and increase the risk of renal function deterioration.
Lithium
Increased serum lithium concentrations and toxicity have been reported.
Statins
Sacubitril may inhibit OATP1B1 and OATP1B3 transporters, potentially increasing exposure to co-administered statins.
ACE inhibitors
Concomitant use is contraindicated due to increased risk of angioedema. Do not administer within 36 hours of switching from or to an ACE inhibitor.
Potassium-sparing diuretics/Potassium supplements
May lead to increases in serum potassium.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include profound hypotension and dizziness. Treatment is symptomatic and supportive, focusing on maintaining blood pressure and hydration.
Pregnancy & Lactation
Contraindicated during pregnancy due to fetal toxicity. Not recommended during breastfeeding as it is unknown if it is excreted in human milk.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from manufacturing date when stored under recommended conditions.
Availability
Available in retail pharmacies and hospitals
Approval Status
Approved by FDA, EMA, DGDA
Patent Status
Patented, protection expected until late 2020s/early 2030s
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
